Needham analyst Ami Fadia maintained a Buy rating on Pharma Mar SA (PHMMF – Research Report) today and set a price target of €108.00. The company’s shares closed last Friday at $95.79.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fadia covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Merus, and Bicycle Therapeutics. According to TipRanks, Fadia has an average return of 2.1% and a 44.70% success rate on recommended stocks.
Currently, the analyst consensus on Pharma Mar SA is a Moderate Buy with an average price target of $112.53.
The company has a one-year high of $110.19 and a one-year low of $25.62. Currently, Pharma Mar SA has an average volume of 1,486.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PHMMF in relation to earlier this year.
Read More on PHMMF: